Successful tyrosine kinase inhibitor discontinuation outside clinical trials — data from the population‐based Swedish chronic myeloid leukaemia registryHjalmar Flygt, Johan Richter, Kristina Myhr‐Eriksson et al.|British Journal of Haematology|2021Cited by 15
Long‐term tolerability and efficacy after initial PegIFN‐α addition to dasatinib in CML‐CP: Five‐year follow‐up of the NordCML007 studyHjalmar Flygt, Henrik Hjorth‐Hansen, Stina Söderlund et al.|European Journal Of Haematology|2021Cited by 10
The impact of Covid-19 in patients with chronic myeloid leukemia—a nationwide population-based studyTorsten Dahlén, Fredrik Nyberg, Hjalmar Flygt et al.|Leukemia|2023Cited by 5